A DOUBLE BLIND, PLACEBO CONTROLLED, PARALLEL GROUP, MULTICENTRE, RANDOMISED PHASE III STUDY OF DISEASE-RELATED SYMPTOMS COMPARING ZD1839 (IRESSA)(250MG TABLET) PLUS BEST SUPPORTIVE CARE (BSC) VERSUS PLACEBO PLUS BSC IN SYMPTOMATIC PATIENTS WITH ADVANCED NSCLC WHO HAVE RECEIVED ONE OR TWO PRIOR CHEMOTHERAPY REGIMENS AND ARE REFRACTORY OR INTOLERANT TO THEIR MOST RECENT REGIMENS

Study identifier:1839IL/0710

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A DOUBLE BLIND, PLACEBO CONTROLLED, PARALLEL GROUP, MULTICENTRE, RANDOMISED PHASE III STUDY OF DISEASE-RELATED SYMPTOMS COMPARING ZD1839 (IRESSA)(250MG TABLET) PLUS BEST SUPPORTIVE CARE (BSC) VERSUS PLACEBO PLUS BSC IN SYMPTOMATIC PATIENTS WITH ADVANCED NSCLC WHO HAVE RECEIVED ONE OR TWO PRIOR CHEMOTHERAPY REGIMENS AND ARE REFRACTORY OR INTOLERANT TO THEIR MOST RECENT REGIMENS

Medical condition

lung cancer

Phase

Phase 3

Healthy volunteers

Study drug

Sex

Actual Enrollment

Study type

Interventional

Age

Date

Study Start Date: 01 Mar 2004

Primary Completion Date: -

Study Completion Date: -

Study design

Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Nov 2013 by AstraZeneca

Collaborators

Inclusion and exclusion criteria

No locations available

Arms	Assigned Interventions

"There is no result for the study"

Documents available

https://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_6111&studyid=2024&filename=CSR-1839IL-0710.pdf
Download
CSR-1839IL-0710.pdf
Download
Trial Results Summaries
Available here

Official Title

Medical condition

Phase

Healthy volunteers

Study drug

Sex

Actual Enrollment

Study type

Age

Date

Study design

Verification:

Sponsors

Collaborators

Inclusion Criteria

Exclusion Criteria

Documents available

https://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_6111&studyid=2024&filename=CSR-1839IL-0710.pdf

CSR-1839IL-0710.pdf

Trial Results Summaries